Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process.

Wang C, Scott SM, Subramanian K, Loguercio S, Zhao P, Hutt DM, Farhat NY, Porter FD, Balch WE.

Nat Commun. 2019 Nov 7;10(1):5052. doi: 10.1038/s41467-019-12969-x.

2.

Individualized Management of Genetic Diversity in Niemann-Pick C1 through Modulation of the Hsp70 Chaperone System.

Wang C, Scott SM, Sun S, Zhao P, Hutt DM, Shao H, Gestwicki JE, Balch WE.

Hum Mol Genet. 2019 Sep 11. pii: ddz215. doi: 10.1093/hmg/ddz215. [Epub ahead of print]

PMID:
31509197
3.

HDAC inhibitors rescue multiple disease-causing CFTR variants.

Anglès F, Hutt DM, Balch WE.

Hum Mol Genet. 2019 Jun 15;28(12):1982-2000. doi: 10.1093/hmg/ddz026.

PMID:
30753450
4.

Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis.

Soberanes S, Misharin AV, Jairaman A, Morales-Nebreda L, McQuattie-Pimentel AC, Cho T, Hamanaka RB, Meliton AY, Reyfman PA, Walter JM, Chen CI, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Antalek M, Abdala-Valencia H, Chiarella SE, Sun KA, Woods PS, Ghio AJ, Jain M, Perlman H, Ridge KM, Morimoto RI, Sznajder JI, Balch WE, Bhorade SM, Bharat A, Prakriya M, Chandel NS, Mutlu GM, Budinger GRS.

Cell Metab. 2019 Feb 5;29(2):503. doi: 10.1016/j.cmet.2018.12.001. No abstract available.

5.

Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis.

Soberanes S, Misharin AV, Jairaman A, Morales-Nebreda L, McQuattie-Pimentel AC, Cho T, Hamanaka RB, Meliton AY, Reyfman PA, Walter JM, Chen CI, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Antalek M, Abdala-Valencia H, Chiarella SE, Sun KA, Woods PS, Ghio AJ, Jain M, Perlman H, Ridge KM, Morimoto RI, Sznajder JI, Balch WE, Bhorade SM, Bharat A, Prakriya M, Chandel NS, Mutlu GM, Budinger GRS.

Cell Metab. 2019 Feb 5;29(2):335-347.e5. doi: 10.1016/j.cmet.2018.09.019. Epub 2018 Oct 11. Erratum in: Cell Metab. 2019 Feb 5;29(2):503.

PMID:
30318339
6.

Bridging Genomics to Phenomics at Atomic Resolution through Variation Spatial Profiling.

Wang C, Balch WE.

Cell Rep. 2018 Aug 21;24(8):2013-2028.e6. doi: 10.1016/j.celrep.2018.07.059.

7.

Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation.

Hutt DM, Loguercio S, Roth DM, Su AI, Balch WE.

J Biol Chem. 2018 Aug 31;293(35):13477-13495. doi: 10.1074/jbc.RA118.003192. Epub 2018 Jul 13.

8.

Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy.

Hutt DM, Mishra SK, Roth DM, Larsen MB, Angles F, Frizzell RA, Balch WE.

J Biol Chem. 2018 Aug 31;293(35):13682-13695. doi: 10.1074/jbc.RA118.002607. Epub 2018 Jul 9.

9.

A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Hutt DM, Loguercio S, Campos AR, Balch WE.

J Mol Biol. 2018 Sep 14;430(18 Pt A):2951-2973. doi: 10.1016/j.jmb.2018.06.017. Epub 2018 Jun 18.

10.

Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease.

Subramanian K, Rauniyar N, Lavalleé-Adam M, Yates JR 3rd, Balch WE.

Mol Cell Proteomics. 2017 Nov;16(11):1938-1957. doi: 10.1074/mcp.M116.064949. Epub 2017 Aug 31.

11.

Measuring the Effect of Histone Deacetylase Inhibitors (HDACi) on the Secretion and Activity of Alpha-1 Antitrypsin.

Wang C, Bouchecareilh M, Balch WE.

Methods Mol Biol. 2017;1639:185-193. doi: 10.1007/978-1-4939-7163-3_18.

12.

Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.

Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, Chen CI, Anekalla KR, Joshi N, Williams KJN, Abdala-Valencia H, Yacoub TJ, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Gates K, Lam AP, Nicholson TT, Homan PJ, Soberanes S, Dominguez S, Morgan VK, Saber R, Shaffer A, Hinchcliff M, Marshall SA, Bharat A, Berdnikovs S, Bhorade SM, Bartom ET, Morimoto RI, Balch WE, Sznajder JI, Chandel NS, Mutlu GM, Jain M, Gottardi CJ, Singer BD, Ridge KM, Bagheri N, Shilatifard A, Budinger GRS, Perlman H.

J Exp Med. 2017 Aug 7;214(8):2387-2404. doi: 10.1084/jem.20162152. Epub 2017 Jul 10.

13.

The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop.

Budinger GRS, Kohanski RA, Gan W, Kobor MS, Amaral LA, Armanios M, Kelsey KT, Pardo A, Tuder R, Macian F, Chandel N, Vaughan D, Rojas M, Mora AL, Kovacs E, Duncan SR, Finkel T, Choi A, Eickelberg O, Chen D, Agusti A, Selman M, Balch WE, Busse P, Lin A, Morimoto R, Sznajder JI, Thannickal VJ.

J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1492-1500. doi: 10.1093/gerona/glx090. Review.

14.

Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells.

Pipalia NH, Subramanian K, Mao S, Ralph H, Hutt DM, Scott SM, Balch WE, Maxfield FR.

J Lipid Res. 2017 Apr;58(4):695-708. doi: 10.1194/jlr.M072140. Epub 2017 Feb 13. Erratum in: J Lipid Res. 2017 Sep;58(9):1932.

15.

From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.

Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, Hong JS, Pollard HB, Guggino WB, Balch WE, Skach WR, Cutting GR, Frizzell RA, Sheppard DN, Cyr DM, Sorscher EJ, Brodsky JL, Lukacs GL.

Mol Biol Cell. 2016 Feb 1;27(3):424-33. doi: 10.1091/mbc.E14-04-0935.

16.

∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.

Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M, Balch WE, Yates JR 3rd.

Nature. 2015 Dec 24;528(7583):510-6. doi: 10.1038/nature15729. Epub 2015 Nov 30.

17.

Hallmarks of therapeutic management of the cystic fibrosis functional landscape.

Amaral MD, Balch WE.

J Cyst Fibros. 2015 Nov;14(6):687-99. doi: 10.1016/j.jcf.2015.09.006. Epub 2015 Oct 29. Review.

18.

Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis.

Rauniyar N, Subramanian K, Lavallée-Adam M, Martínez-Bartolomé S, Balch WE, Yates JR 3rd.

Mol Cell Proteomics. 2015 Jul;14(7):1734-49. doi: 10.1074/mcp.M114.045609. Epub 2015 Apr 14.

19.

Proteostatic hotspots in amyloid fibrils protect us from neurodegeneration.

Singh JK, Balch WE.

Dev Cell. 2015 Mar 23;32(6):659-60. doi: 10.1016/j.devcel.2015.03.009.

20.

Blue journal conference. Aging and susceptibility to lung disease.

Thannickal VJ, Murthy M, Balch WE, Chandel NS, Meiners S, Eickelberg O, Selman M, Pardo A, White ES, Levy BD, Busse PJ, Tuder RM, Antony VB, Sznajder JI, Budinger GR.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):261-9. doi: 10.1164/rccm.201410-1876PP. Review.

21.

Modulation of the maladaptive stress response to manage diseases of protein folding.

Roth DM, Hutt DM, Tong J, Bouchecareilh M, Wang N, Seeley T, Dekkers JF, Beekman JM, Garza D, Drew L, Masliah E, Morimoto RI, Balch WE.

PLoS Biol. 2014 Nov 18;12(11):e1001998. doi: 10.1371/journal.pbio.1001998. eCollection 2014 Nov.

22.

Quantitative proteomic profiling reveals differentially regulated proteins in cystic fibrosis cells.

Rauniyar N, Gupta V, Balch WE, Yates JR 3rd.

J Proteome Res. 2014 Nov 7;13(11):4668-75. doi: 10.1021/pr500370g. Epub 2014 May 21.

23.

Q-bodies monitor the quinary state of the protein fold.

Roth DM, Balch WE.

Nat Cell Biol. 2013 Oct;15(10):1137-9. doi: 10.1038/ncb2857.

PMID:
24084862
24.
25.

Malfolded protein structure and proteostasis in lung diseases.

Balch WE, Sznajder JI, Budinger S, Finley D, Laposky AD, Cuervo AM, Benjamin IJ, Barreiro E, Morimoto RI, Postow L, Weissman AM, Gail D, Banks-Schlegel S, Croxton T, Gan W.

Am J Respir Crit Care Med. 2014 Jan 1;189(1):96-103. doi: 10.1164/rccm.201306-1164WS.

26.

Insulin biosynthetic interaction network component, TMEM24, facilitates insulin reserve pool release.

Pottekat A, Becker S, Spencer KR, Yates JR 3rd, Manning G, Itkin-Ansari P, Balch WE.

Cell Rep. 2013 Sep 12;4(5):921-30. doi: 10.1016/j.celrep.2013.07.050. Epub 2013 Sep 5.

27.

ML346: A Novel Modulator of Proteostasis for Protein Conformational Diseases.

Calamini B, Silva MC, Madoux F, Hutt DM, Khanna S, Chalfant MA, Allais C, Ouizem S, Saldanha SA, Ferguson J, Mercer BA, Michael C, Tait BD, Garza D, Balch WE, Roush WR, Morimoto RI, Hodder P.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Apr 5].

28.

Diffuse lung disease in children: summary of a scientific conference.

Hamvas A, Deterding R, Balch WE, Schwartz DA, Albertine KH, Whitsett JA, Cardoso WV, Kotton DN, Kourembanas S, Hagood JS.

Pediatr Pulmonol. 2014 Apr;49(4):400-9. doi: 10.1002/ppul.22805. Epub 2013 Jun 24.

29.

Diversity in the origins of proteostasis networks--a driver for protein function in evolution.

Powers ET, Balch WE.

Nat Rev Mol Cell Biol. 2013 Apr;14(4):237-48. doi: 10.1038/nrm3542. Epub 2013 Mar 6. Review.

30.

Expanding proteostasis by membrane trafficking networks.

Hutt DM, Balch WE.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a013383. doi: 10.1101/cshperspect.a013383. Review.

31.

Protein folding: salty sea regulators of cystic fibrosis.

Gupta V, Balch WE.

Nat Chem Biol. 2013 Jan;9(1):12-4. doi: 10.1038/nchembio.1144. No abstract available.

PMID:
23238682
32.

Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.

Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE.

J Biol Chem. 2012 Nov 2;287(45):38265-78. doi: 10.1074/jbc.M112.404707. Epub 2012 Sep 20.

33.

Translational attenuation differentially alters the fate of disease-associated fibulin proteins.

Hulleman JD, Balch WE, Kelly JW.

FASEB J. 2012 Nov;26(11):4548-60. doi: 10.1096/fj.11-202861. Epub 2012 Aug 7.

34.

A chaperone trap contributes to the onset of cystic fibrosis.

Coppinger JA, Hutt DM, Razvi A, Koulov AV, Pankow S, Yates JR 3rd, Balch WE.

PLoS One. 2012;7(5):e37682. doi: 10.1371/journal.pone.0037682. Epub 2012 May 31.

35.

Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease.

Bouchecareilh M, Balch WE.

Curr Mol Med. 2012 Aug;12(7):815-26. Review.

PMID:
22697348
36.

FK506 binding protein 8 peptidylprolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability.

Hutt DM, Roth DM, Chalfant MA, Youker RT, Matteson J, Brodsky JL, Balch WE.

J Biol Chem. 2012 Jun 22;287(26):21914-25. doi: 10.1074/jbc.M112.339788. Epub 2012 Apr 2.

37.

Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Solomon JP, Page LJ, Balch WE, Kelly JW.

Crit Rev Biochem Mol Biol. 2012 May-Jun;47(3):282-96. doi: 10.3109/10409238.2012.661401. Epub 2012 Feb 24. Review.

38.

Small-molecule proteostasis regulators for protein conformational diseases.

Calamini B, Silva MC, Madoux F, Hutt DM, Khanna S, Chalfant MA, Saldanha SA, Hodder P, Tait BD, Garza D, Balch WE, Morimoto RI.

Nat Chem Biol. 2011 Dec 25;8(2):185-96. doi: 10.1038/nchembio.763.

39.

Compromised mutant EFEMP1 secretion associated with macular dystrophy remedied by proteostasis network alteration.

Hulleman JD, Kaushal S, Balch WE, Kelly JW.

Mol Biol Cell. 2011 Dec;22(24):4765-75. doi: 10.1091/mbc.E11-08-0695. Epub 2011 Oct 26.

40.

Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.

Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant M, Montero A, Leman LJ, Burkle R, Maryanoff BE, Balch WE, Ghadiri MR.

ACS Med Chem Lett. 2011 Jul 21;2(9):703-707.

41.

CFTR Folding Consortium: methods available for studies of CFTR folding and correction.

Peters KW, Okiyoneda T, Balch WE, Braakman I, Brodsky JL, Guggino WB, Penland CM, Pollard HB, Sorscher EJ, Skach WR, Thomas PJ, Lukacs GL, Frizzell RA.

Methods Mol Biol. 2011;742:335-53. doi: 10.1007/978-1-61779-120-8_20.

42.

Application of mass spectrometry to study proteomics and interactomics in cystic fibrosis.

Balch WE, Yates JR 3rd.

Methods Mol Biol. 2011;742:227-47. doi: 10.1007/978-1-61779-120-8_14.

PMID:
21547736
43.

Introduction to section II: omics in the biology of cystic fibrosis.

Balch WE.

Methods Mol Biol. 2011;742:189-91. doi: 10.1007/978-1-61779-120-8_11.

PMID:
21547733
44.

Proteostasis: a new therapeutic paradigm for pulmonary disease.

Bouchecareilh M, Balch WE.

Proc Am Thorac Soc. 2011 May;8(2):189-95. doi: 10.1513/pats.201008-055MS.

45.

Di-acidic motifs in the membrane-distal C termini modulate the transport of angiotensin II receptors from the endoplasmic reticulum to the cell surface.

Zhang X, Dong C, Wu QJ, Balch WE, Wu G.

J Biol Chem. 2011 Jun 10;286(23):20525-35. doi: 10.1074/jbc.M111.222034. Epub 2011 Apr 20.

46.

Emergent properties of proteostasis in managing cystic fibrosis.

Balch WE, Roth DM, Hutt DM.

Cold Spring Harb Perspect Biol. 2011 Feb 1;3(2). pii: a004499. doi: 10.1101/cshperspect.a004499. Review.

47.

Protein folding: Protection from the outside.

Powers ET, Balch WE.

Nature. 2011 Mar 3;471(7336):42-3. doi: 10.1038/471042a. No abstract available.

PMID:
21368816
48.

Modeling general proteostasis: proteome balance in health and disease.

Roth DM, Balch WE.

Curr Opin Cell Biol. 2011 Apr;23(2):126-34. doi: 10.1016/j.ceb.2010.11.001. Epub 2010 Dec 3. Review.

49.

Emergent properties of proteostasis-COPII coupled systems in human health and disease.

Routledge KE, Gupta V, Balch WE.

Mol Membr Biol. 2010 Nov;27(8):385-97. doi: 10.3109/09687688.2010.524894. Epub 2010 Nov 5. Review.

PMID:
21054154
50.

Proteostasis strategies for restoring alpha1-antitrypsin deficiency.

Bouchecareilh M, Conkright JJ, Balch WE.

Proc Am Thorac Soc. 2010 Nov;7(6):415-22. doi: 10.1513/pats.201001-016AW. Review.

Supplemental Content

Loading ...
Support Center